Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States LFSPROShiny implements two models that have been validated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback